A Phase 1/2 interventional study of Alisertib (MLN8237) and Rituximab in Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma and Mantle Cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 25 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-27.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.
Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 108th largest by enrollment of the 211 interventional ones that give a count, is one of 10 that started in 2011, is one of 25 in phase 1/2, and was the 116th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:
The First Hospital of Jilin University · Sites in China
Ages 65+
Paolo Caimi, MD · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Ou Bai, MD/PHD · Sites in China
Ages 70+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 60+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
218 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 146 · Phase 3 32 · Phase 4 3
First in 1993; this study’s year is marked. 10 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is close to the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 46 across the 211 interventional studies. Of the 142 that completed or were terminated, 61 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 218 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 7 studies filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
7 of the studies testing rituximab in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06573645Phase 3Xia YiA Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | 2027-01-12 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT04978584M.D. Anderson Cancer CenterRituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | 2027-01-16 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma (TFL) treated with rituximab and vincristine. The study has three parts as follows:
Phase 1, Part 1: Safety lead-in cohort to evaluate alisertib (MLN8237) and rituximab.
Phase 1, Part 2: Dose escalation cohort to evaluate alisertib (MLN8237) + Rituximab + Vincristine and determine Phase 2 dose. Patients with other types of B-cell lymphoma (including mantle cell or Burkitt's lymphoma may enroll in Parts 1 and 2.
Phase 2: Alisertib (MLN8237) + Rituximab + Vincristine in patients with relapsed or refractory DLBCL or TFL at recommended Phase 2 dose.
Note that in 2013 Sponsor decision was taken to not initiate the phase 2 portion of the trial, which would have investigated the triplet at the recommended phase 2 dose identified in part 2. This decision was based on reprioritization within the company and not on any clinical or safety outcomes observed.
The drug tested in this study was called alisertib. Alisertib was tested to treat people who have relapsed or refractory diffuse large B-cell lymphoma or other aggressive B-cell lymphomas. This study looked at safety, any anti-tumor effect, and it also determined a recommended dose of alisertib plus rituximab and alisertib plus rituximab and vincristine to take into further studies. Pharmacokinetic blood samples were studied to characterize any effects on the concentration of each of the drugs when administered together .
The study enrolled 45 patients. Participants received the following treatments:
Phase 1
All participants were asked to take one alisertib table twice a day for 7 days in each cycle for up to 8 cycles along with rituximab on Day 1 of each cycle; some patients also received vincristine on Day 1 and Day 8 of each cycle. All participants with documented disease response or stabilization could continue with alisertib single-agent therapy for an additional 2 years or more.
This multi-center trial was conducted in the USA. The overall time to participate in this study was up to 5.2 years. Participants made multiple visits to the clinic, plus a final visit 30 days after receiving their last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alisertib 50 mg, enteric coated tablets (ECT), orally, twice daily (BID), on Days 1 to 7 followed by a 14-day rest period in 21-day cycles plus rituximab 375 mg/m\^2, intravenous (IV), infusion on Day 1 of each 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
Drug: Alisertib (MLN8237) · Drug: Rituximab
Alisertib 30 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m\^2, IV, infusion on Day 1, plus vincristine 1.4 mg/m\^2 (max 2 mg), IV, on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
Drug: Alisertib (MLN8237) · Drug: Rituximab · Drug: Vincristine
Alisertib 40 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m\^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m\^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
Drug: Alisertib (MLN8237) · Drug: Rituximab · Drug: Vincristine
Alisertib 50 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m\^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m\^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
Drug: Alisertib (MLN8237) · Drug: Rituximab · Drug: Vincristine
Phase 2: Alisertib (MLN8237) at the Recommended Phase 2 Dose, ECT orally twice/day on Days 1-7 \& rituximab as an IV infusion on Day 1 \& vincristine IV on Days 1 \& 8 in a 21 Day cycle for up to 8 cycles was planned but not conducted.
Drug: Alisertib (MLN8237) · Drug: Rituximab · Drug: Vincristine
Alisertib (MLN8237) enteric coated tablet (ECT).
Rituximab IV infusion.
Vincristine IV Infusion.
Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1]
Vital sign parameters: blood pressure, heart rate and temperature determined by the investigator to be clinically significant were reported as adverse events.
Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 1]
Abnormal ECGs findings determined by the investigator to be clinically significant were reported as adverse events.
Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 1]
Abnormal changes in MUGA and ECHO findings determined by the investigator to be clinically significant were reported as adverse events.
Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Number of Participants With Clinically Significant Changes in Physical Examination Findings [Phase 1]
Abnormal Physical Examination findings determined by the investigator to be clinically significant were reported as Adverse Events.
Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Number of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 1]
Abnormal treatment-emergent Chemistry and Hematology Laboratory values determined by the investigator to be clinically significant were reported as adverse events.
Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Number of Participants With Treatment-Emergent Adverse Events [Phase 1]
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Overall Response Rate [Phase 2]
Overall Response Rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) as assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
Time frame: At the end of Cycle 2, at the end of every second treatment cycle until 6 months, then every 12 weeks thereafter, approximately 2 years
Overall Response Rate as Assessed by the Investigator [Phase 1]
Overall Response Rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) as assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Complete Response Rate [Phase 2]
Complete response rate was defined as the percentage of participants with Complete Response (CR). CR was assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease.
Time frame: Duration of study until disease progression, approximately 2 years
Duration of Response (DOR) [Phase 2]
DOR was defined as the time from the date of first documentation of a response to the date of first documentation of Progressive Disease (PD).
Time frame: Duration of study until disease progression, approximately 2 years
Progression Free Survival (PFS) [Phase 2]
PFS was defined as the time from the date of first study drug administration to the date of first documentation of PD or death.
Time frame: Duration of study until disease progression, approximately 2 years
Number of Participants With Treatment-Emergent Adverse Events [Phase 2]
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From screening period to 30 days after last dose of study drug, approximately 2 years
Number of Participants With Clinically Significant Vital Signs Findings [Phase 2]
Vital sign parameters: blood pressure, heart rate and temperature determined by the investigator to be clinically significant were reported as adverse events.
Time frame: From screening period to 30 days after last dose of study drug, approximately 2 years
Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 2]
Time frame: From screening period to 30 days after last dose of study drug, approximately 2 years
Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 2]
Time frame: From screening period to 30 days after last dose of study drug, approximately 2 years
Number of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 2]
Time frame: From screening period to 30 days after last dose of study drug, approximately 2 years
Cmax: Maximum Plasma Concentration for Alisertib
Time frame: Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose
Tmax: Time to First Occurrence of Cmax fo Alisertib
Time frame: Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose
AUCt: Area Under the Concentration Time Curve Over the Dosing Interval From Time 0 to Time t for Alisertib
Time frame: Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose
Cmax: Maximum Plasma Concentration for Vincristine
Time frame: Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose
AUCt: Area Under the Concentration-time Time Curve Over the Dosing Interval From Time 0 to Time t for Vincristine
Time frame: Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose
AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for Vincristine
Time frame: Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose
T1/2: Terminal Disposition Phase Half-life for Vincristine
Time frame: Cycles 1 and 2 on Day prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose
Participants took part in the Phase 1 portion of the study at 10 investigative sites in the United States from 09 August 2011 to 05 October 2016. The Phase 2 portion of the study was cancelled by the sponsor.
| Milestone | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg | Phase 2: Alisertib |
|---|---|---|---|---|---|
| Started | 13 | 4 | 25 | 3 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 13 | 4 | 25 | 3 | 0 |
| Withdrew: Progressive disease | 10 | 3 | 11 | 1 | 0 |
| Withdrew: Symptomatic deterioration | 2 | 0 | 4 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 5 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 5 | 1 | 0 |
Vital sign parameters: blood pressure, heart rate and temperature determined by the investigator to be clinically significant were reported as adverse events.
| participants | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| Hypotension | 0 | 0 | 3 | 1 |
| Orthostatic hypotension | 2 | 2 | 0 | 0 |
| Hypertension | 1 | 0 | 0 | 0 |
| Pyrexia | 3 | 0 | 2 | 1 |
Abnormal ECGs findings determined by the investigator to be clinically significant were reported as adverse events.
| participants | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 1] | 0 | 0 | 0 | 0 |
Abnormal changes in MUGA and ECHO findings determined by the investigator to be clinically significant were reported as adverse events.
| participants | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 1] | 0 | 0 | 0 | 0 |
Abnormal Physical Examination findings determined by the investigator to be clinically significant were reported as Adverse Events.
| participants | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Physical Examination Findings [Phase 1] | 0 | 0 | 2 | 2 |
Abnormal treatment-emergent Chemistry and Hematology Laboratory values determined by the investigator to be clinically significant were reported as adverse events.
| participants | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| Anaemia | 6 | 3 | 14 | 2 |
| Neutropenia | 7 | 2 | 11 | 2 |
| Febrile neutropenia | 0 | 0 | 4 | 3 |
| Leukopenia | 8 | 2 | 9 | 3 |
| Lymphopenia | 2 | 2 | 1 | 1 |
| Thrombocytopenia | 7 | 1 | 7 | 3 |
| Hypokalaemia | 5 | 0 | 6 | 2 |
| Hyperkalaemia | 0 | 0 | 1 | 0 |
| Hypomagnesaemia | 2 | 0 | 5 | 1 |
| Hypermagnesaemia | 0 | 0 | 0 | 1 |
| Hypocalcaemia | 2 | 0 | 1 | 1 |
| Hypercalcaemia | 1 | 0 | 2 | 0 |
| Hyperglycaemia | 1 | 1 | 2 | 1 |
| Hypoalbuminaemia | 3 | 0 | 0 | 2 |
| Hyponatraemia | 2 | 0 | 0 | 1 |
| Hypernatraemia | 0 | 0 | 1 | 0 |
| Hypophosphataemia | 1 | 0 | 1 | 1 |
| Neutrophil count decreased | 1 | 0 | 3 | 1 |
| Lymphocyte count decreased | 1 | 0 | 0 | 0 |
| White blood cell count decreased | 0 | 0 | 0 | 1 |
| Aspartate aminotransferase increased | 0 | 0 | 1 | 2 |
| Alanine aminotransferase increased | 0 | 0 | 0 | 2 |
| Blood bilirubin increased | 1 | 0 | 0 | 0 |
| Platelet count decreased | 1 | 0 | 1 | 1 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| participants | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events [Phase 1] | 13 | 4 | 25 | 3 |
Overall Response Rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) as assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
No measurements were reported for this outcome.
Overall Response Rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) as assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.
| percentage of participants | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| Overall Response Rate as Assessed by the Investigator [Phase 1] | 25 (5 to 57) | 33 (0.84 to 91) | 45 (23 to 68) | 50 (1 to 99) |
Complete response rate was defined as the percentage of participants with Complete Response (CR). CR was assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease.
No measurements were reported for this outcome.
DOR was defined as the time from the date of first documentation of a response to the date of first documentation of Progressive Disease (PD).
No measurements were reported for this outcome.
PFS was defined as the time from the date of first study drug administration to the date of first documentation of PD or death.
No measurements were reported for this outcome.
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
No measurements were reported for this outcome.
Vital sign parameters: blood pressure, heart rate and temperature determined by the investigator to be clinically significant were reported as adverse events.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
| nanoMolar (nM) | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| Day 1 | 1624.1 ± 929.68 | 893.3 ± 350.03 | 1159.7 ± 391.78 | 1746.7 ± 594.75 |
| Day 7 | 2915.8 ± 1537.03 | 1672.5 ± 183.92 | 2223.3 ± 1217.22 | 3670.0 ± 1541.49 |
| hours (hr) | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| Day 1 | 3.0 (2 to 8) | 3.5 (3 to 6) | 3.0 (1 to 12) | 6.1 (3 to 12) |
| Day 7 | 2.0 (0 to 8) | 3.1 (2 to 6) | 3.1 (2 to 8) | 2.5 (2 to 3) |
| nanomoles/liter*hour (nmol/L*hr) | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| Day 1 | 10116.7 ± 6683.97 | 5817.5 ± 2966.26 | 8005.9 ± 3251.32 | 13096.7 ± 7453.39 |
| Day 7 | 21812.5 ± 13090.21 | 12227.5 ± 3480.09 | 17996.0 ± 11555.15 | 33800.0 ± 16263.46 |
| ng/mL | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|
| Cycle 1, Day 1 | 132.2 ± 54.57 | 105.4 ± 78.93 | 158.4 ± 67.94 |
| Cycle 2, Day 1 | 113.9 ± 53.86 | 124.4 ± 157.70 | 122.3 ± 36.42 |
| ng/mL*hr | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|
| Cycle 1, Day 1 | 69.8 ± 9.92 | 69.1 ± 33.24 | 104.1 ± 43.34 |
| Cycle 2, Day 1 | 60.8 ± 2.26 | 72.8 ± 30.40 | 72.2 ± 32.60 |
| ng/mL*hr | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|
| Cycle 1, Day 1 | 77.9 ± 11.25 | 84.8 ± 36.21 | 116.8 ± 44.95 |
| Cycle 2, Day 1 | 69.0 ± 4.45 | 82.7 ± 35.39 | — |
| nanogram/milliliter (ng/mL) | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|
| Cycle 1, Day 1 | 20.2 ± 5.04 | 20.0 ± 5.89 | 25.6 ± 4.55 |
| Cycle 2, Day 1 | 19.9 ± 0.92 | 20.2 ± 4.66 | — |
Collected over First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Lead-in | — | 6/13 (46.2%) | 13/13 (100%) |
| Dose Escalation, Alisertib 30 mg | — | 1/4 (25%) | 4/4 (100%) |
| Dose Escalation, Alisertib 40 mg | — | 12/25 (48%) | 25/25 (100%) |
| Dose Escalation, Alisertib 50 mg | — | 3/3 (100%) | 3/3 (100%) |
| Event | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/13 | 0/4 | 3/25 | 3/3 |
| StomatitisGastrointestinal disorders | 0/13 | 0/4 | 0/25 | 2/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/13 | 0/4 | 0/25 | 1/3 |
| FatigueGeneral disorders | 0/13 | 0/4 | 0/25 | 1/3 |
| Clostridium difficile colitisInfections and infestations | 0/13 | 0/4 | 0/25 | 1/3 |
| Enterobacter bacteraemiaInfections and infestations | 0/13 | 0/4 | 0/25 | 1/3 |
| Spinal cord neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/13 | 1/4 | 0/25 | 0/3 |
| Spinal cord compressionNervous system disorders | 0/13 | 1/4 | 0/25 | 0/3 |
| AnaemiaBlood and lymphatic system disorders | 2/13 | 0/4 | 1/25 | 0/3 |
| PyrexiaGeneral disorders | 2/13 | 0/4 | 2/25 | 0/3 |
| Event | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg |
|---|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 8/13 | 2/4 | 9/25 | 3/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/13 | 1/4 | 8/25 | 3/3 |
| AnaemiaBlood and lymphatic system disorders | 6/13 | 3/4 | 15/25 | 2/3 |
| NeutropeniaBlood and lymphatic system disorders | 7/13 | 2/4 | 11/25 | 2/3 |
| FatigueGeneral disorders | 4/13 | 2/4 | 11/25 | 2/3 |
| HypokalaemiaMetabolism and nutrition disorders | 4/13 | 0/4 | 6/25 | 2/3 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 3/13 | 0/4 | 0/25 | 2/3 |
| Urinary tract infectionInfections and infestations | 1/13 | 0/4 | 6/25 | 2/3 |
| Aspartate aminotransferase increasedInvestigations | 0/13 | 0/4 | 1/25 | 2/3 |
| Alanine aminotransferase increasedInvestigations | 0/13 | 0/4 | 0/25 | 2/3 |
Safety Population was defined as all participants who receive any amount of alisertib.
| Age, Continuous(years) | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg | Total |
|---|---|---|---|---|---|
| Mean | 60.3 ± 14.06 | 51.3 ± 21.65 | 62.8 ± 10.51 | 66.7 ± 12.86 | 61.3 ± 12.89 |
| Sex: Female, Male(Participants) | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg | Total |
|---|---|---|---|---|---|
| Female | 3 | 1 | 10 | 2 | 16 |
| Male | 10 | 3 | 15 | 1 | 29 |
| Race/Ethnicity, Customized(participants) | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 1 | 6 | 1 | 15 |
| Not Hispanic or Latino | 6 | 3 | 19 | 2 | 30 |
| Race/Ethnicity, Customized(participants) | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg | Total |
|---|---|---|---|---|---|
| White | 12 | 4 | 21 | 3 | 40 |
| Black or African American | 0 | 0 | 2 | 0 | 2 |
| Asian | 1 | 0 | 0 | 0 | 1 |
| Other | 0 | 0 | 1 | 0 | 1 |
| Not Reported | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg | Total |
|---|---|---|---|---|---|
| United States | 13 | 4 | 25 | 3 | 45 |
| Height(cm) | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg | Total |
|---|---|---|---|---|---|
| Mean | 167.9 ± 10.90 | 178.2 ± 7.15 | 168.4 ± 10.76 | 166.5 ± 5.32 | 169.0 ± 10.44 |
| Weight(kg) | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg | Total |
|---|---|---|---|---|---|
| Mean | 70.98 ± 16.18 | 89.51 ± 23.89 | 82.21 ± 16.4 | 71.94 ± 14.55 | 78.93 ± 17.46 |
| Body Surface Area(m^2) | Safety Lead-in | Dose Escalation, Alisertib 30 mg | Dose Escalation, Alisertib 40 mg | Dose Escalation, Alisertib 50 mg | Total |
|---|---|---|---|---|---|
| Mean | 1.815 ± 0.25 | 2.093 ± 0.31 | 1.940 ± 0.23 | 1.823 ± 0.21 | 1.910 ± 0.25 |
Ran from Aug 2011 to primary completion in Feb 2015, 41 months.
Results were first posted in Mar 2018, 3 years 1 month after primary completion. A results delay was requested in Nov 2016.
Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 41 months is below that.
Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MLN 8237 · Rituximab
Lymphoma, Large B-Cell, Diffuse →
Millennium Pharmaceuticals, Inc. →